Healthcare >> CEO Interviews >> September 20, 1999
REBECCA E. KEELER serves as the President and CEO of Dimethaid Research
Inc. Since joining Dimethaid in 1990, she has led the company's
transition from a contract drug manufacturer to what it is today a
pharmaceutical company developing its own proprietary drug delivery
technology. Ms. Keeler oversaw the clinical development of PENNSAIDR'
Lotion, through all phases of study to its regulatory submission for
marketing approval in Canada, the U.K., and the U.S. Ms. Keeler has also
led Dimethaid in a number of equity offerings, including a public
offering of over $30 million in 1997. The Company is listed for trading
on the Toronto Stock Exchange. Trained as a corporate insolvency
lawyer, Ms. Keeler practiced law in Toronto with Smith Lyons prior to
joining Dimethaid. She has a degree in psychology and economics from
York University and a law degree from Osgoode Hall Law School. Profile
enough of a historical perspective to put us into context. Then bring us
up to date and tell us what you see as the company and as
